| 2026-05-28 | Press release | BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorde |
| 2026-05-15 | Press release | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results |
| 2026-04-17 | Press release | BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment fo |
| 2026-04-08 | Press release | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingua |
| 2026-04-01 | Press release | BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of |
| 2026-03-27 | Press release | BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALM |
| 2026-03-11 | Press release | BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering |
| 2026-03-10 | Press release | BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering |
| 2026-03-05 | Press release | BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatm |
| 2026-02-19 | Press release | BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Trea |
| 2026-02-12 | Press release | BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At- |
| 2026-01-20 | Press release | BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Ex |
| 2026-01-12 | Press release | BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting |
| 2026-01-07 | Press release | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® |
| 2025-03-27 | Press release | BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 |
| 2024-11-14 | Press release | BioXcel Therapeutics Reports Third Quarter 2024 Financial Results |
| 2024-08-06 | Press release | BioXcel Therapeutics Reports Second Quarter 2024 Financial Results |
| 2024-05-09 | Press release | BioXcel Therapeutics Reports First Quarter 2024 Financial Results |
| 2024-03-12 | Press release | BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 |
| 2023-11-14 | Press release | BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strate |
| 2023-08-14 | Press release | BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization |
| 2023-05-08 | Press release | BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights |
| 2023-03-09 | Press release | BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights |
| 2022-11-10 | Press release | BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights |
| 2022-08-09 | Press release | BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights |
| 2022-05-09 | Press release | BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights |
| 2022-03-10 | Press release | BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights |
| 2021-11-10 | Press release | BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights |
| 2021-08-10 | Press release | Earnings Release |
| 2021-05-10 | Press release | Earnings Release |
| Press release | BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in |
| Press release | BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmed |